ACC latest: Lilly, Merck, Pfizer, Novartis and more unveil key data

Tracy Staton You missed the American College of Cardiology meeting. That's OK. The most newsworthy research coming out of the meeting is gathered right here, with almost every Big ...

Merck treads water in Q4 as Keytruda helps offset Remicade suffering

Tracy Staton Merck & Co. took a one-two punch in the fourth quarter. Revenue from two top-selling franchises–Januvia and Remicade–slid, dragging overall ...

Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie

Carly Helfand Industry watchers have long been speculating on how Merck would take on heavyweights Gilead and AbbVie when it priced its new hep C regimen. And now, they have their answer: ...

Merck lines up for a quick approval with its C. diff therapy

Damian Garde Merck is nearing FDA approval for its Clostridium difficile-fighting antibody, picking up the agency's priority review designation with the promise of a shortened vetting ...

Merck teams with Affimed on immuno-oncology combo

John Carroll Germany’s Affimed has inked a deal that makes it the latest in a long string of biotechs to partner up with Merck on a combination study using the PD-1 blockbuster ...

It’s Merck vs. Merck as name confusion, complicated by social media, leads to legal showdown

Eric Palmer Merck has won a legal battle over Merck, which in return says it will file a lawsuit against Merck. It sounds confusing, but confusion is the essence of the legal battle ...

Merck reaches $830M settlement in long-running Vioxx litigation

Emily Wasserman Merck is closing a chapter in its seemingly never-ending saga for its painkiller Vioxx, agreeing to pay more than $ 800 million to settle a lawsuit over the med years ...

CEO Frazier expects Merck to be player in hep C market, M&A this year

Eric Palmer Merck & Co.'s CEO Kenneth Frazier expects his company to be a player in that lucrative hepatitis C market again with the anticipated approval this month of its hep ...

Merck buys out IOmet, adding new immuno-oncology tech

John Carroll Merck has snagged Edinburgh-based IOmet for an undisclosed sum, adding a preclinical pipeline of therapies that target the IDO/TDO pathways that may help spur an immune ...

Pfizer, Merck KGaA launch two more PhIII trials for avelumab

John Carroll The companies say that these two Phase III studies bring the late-stage program up to 6 studies, meeting their goal for 2015. FierceBiotech News

After a 7-year odyssey at the FDA, Merck finally wins an OK for Bridion

John Carroll For the past 7 years Merck has maintained a star rating by its program for Bridion (sugammadex), remaining convinced of its big market potential and staying upbeat after ...

Merck poised to win bigger market for cholesterol-fighting Zetia

Tracy Staton Merck & Co.'s cholesterol drug Zetia gets another day in the spotlight on Monday. An FDA advisory panel is debating results from an outcomes trial, Improve-It, ...
Page 1 of 1112345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS